AZD1656: all 25 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19CompletedNCT04516759Phase 2Results posted
- Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus PatientsCompletedNCT01152385Phase 2Results posted
- Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) PatientsCompletedNCT01020123Phase 2Results posted
- Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 DiabetesCompletedNCT00856908Phase 2Results posted
- Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With MetforminCompletedNCT00817778Phase 2Results posted
- AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNceCompletedNCT05216172Phase 2
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM PatientsCompletedNCT01221545Phase 1
- A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) PatientsCompletedNCT01221519Phase 1
- Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus PatientsCompletedNCT01103622Phase 1
- Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) PatientsCompletedNCT01103609Phase 1
- Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With SimvastatinCompletedNCT01096940Phase 1
- Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes MellitusCompletedNCT01095991Phase 1
- To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656CompletedNCT01083212Phase 1
- Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes MellitusCompletedNCT01082120Phase 1
- To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus PatientsCompletedNCT01069926Phase 1
- Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and SulfonylureaCompletedNCT00995787Phase 1
- To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) PatientsCompletedNCT00916604Phase 1
- To Evaluate 24-hr Glucose After OD vs BD AZD1656CompletedNCT00819884Phase 1
- To Evaluate the Bioavailability of a Tablet of AZD1656CompletedNCT00817505Phase 1
- To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 SuspensionCompletedNCT00790153Phase 1
- To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of MetforminCompletedNCT00774553Phase 1
- To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of InsulinCompletedNCT00768105Phase 1
- A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 DiabetesCompletedNCT00747175Phase 1
- A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy VolunteersCompletedNCT00741689Phase 1
- A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy VolunteersCompletedNCT00726427Phase 1